Comparative Pharmacology
Head-to-head clinical analysis: TRIESENCE versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIESENCE versus ZYLET.
TRIESENCE vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination (Ophthalmic)